Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma
Launched by NANJING NINGQI MEDICINE SCIENCE AND TECHNOLOGY CO., LTD. · Jul 30, 2015
Trial Information
Current as of August 11, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Cytological and histological confirmation(Do not accept single sputum cytology in the diagnosis of patients) in patients diagnosed of lung squamous carcinoma;
- • 2. According to a new IASLC2009 lung cancer TNM stages judged stage IIIB or IV non-small cell lung cancer.
- • 3. Must have at least one evaluated lesion,according to the RRECIST version 1.1 standard (the longest diameter on spiral CT at least 10 mm,the longest diameter on plain CT at least 20 mm);
- • 4. Male or female, age between 18 and 75 years old ;
- • 5. ECOG PS 0\~1;
- • 6. Expected survival period ≥ 3 months or more
- • 7. Enough blood function: absolute neutrophil count (ANC)≥2 x 109 / L and the platelet count≥ 100 x 109 / L and hemoglobin ≥9 g/dL;
- • 8. Enough liver function: total bilirubin acuities≤the upper limit of normal (ULN); AST and ALT acuities ≤2.5 times of the upper limit of normal (ULN); Alkaline phosphatase ≤5 times of the upper limit of normal(ULN);
- • 9. Enough renal function:serum creatinine ≤the limit of normal(ULN) or calculated creatinine clearance≥60 mL/min.
- • 10. The electrocardiogram (ecg) basicaly normal,the body had no to heal wounds
- • 11. No previous anti-tumor drug therapy, or only received for non metastatic tumor of adjuvant or neoadjuvant chemotherapy, but has ended more than six months before the study start.
- • 12. Patients had surgery before,but have more than 4 weeks before the study star, and the patient has recovered;
- • 13. Women with cmpleted uterus before intact in the group within 28 days must have a negative pregnancy test results (unles amenorrhea for 24 months). If the pregnancy test from the first time for more than 7 days,the patients need for urine pregnancy test(within 7 days before the first delivery).
- • 14. Prior to biological agents, especially e. coli genetically engineered products without severe allergic reactions;
- • 15. Sign the informed consent.
- Exclusion Criteria:
- • 1. Pregnancy, nursing mothers, or female patients with fertility but no contraception.
- • 2. Existing serious acute infection, and can not be controlled; Or with fester sex and chronic infection,or wound in delay;
- • 3. Original serious heart disease, including: congestive heart failure, uncontroled high risk arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and resistant hypertension;
- • 4. With uncontroled nerve, mental illness or mental disorders, compliance is poor, can't cooperate and response to treatment; Uncontroled primary brain tumors or CNS metastases illness, with obvious symptoms in cranial hypertension or nerve spirit;
- • 5. With a bleeding tendency
- • 6. Researchers believe that patients should not participate in this test.
About Nanjing Ningqi Medicine Science And Technology Co., Ltd.
Nanjing Ningqi Medicine Science and Technology Co., Ltd. is a leading biopharmaceutical company based in Nanjing, China, dedicated to the research, development, and commercialization of innovative therapeutic solutions. With a strong emphasis on advancing healthcare through cutting-edge technology, the company specializes in developing novel drugs and treatment modalities aimed at addressing unmet medical needs across various therapeutic areas. Nanjing Ningqi is committed to adhering to the highest standards of clinical research and regulatory compliance, ensuring the safety and efficacy of its products while fostering collaborative partnerships within the global healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Soochow, Jiangsu, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials